Clinical trials: Immunoglobulin
Lymphoma
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00073931
- Testing
- filgrastim, sargramostim, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Fred Hutchinson Cancer Center
Triple-Negative Breast Cancer
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 [PD-L1] antibody) administered in…
- Trial name
- IMpassion131 (NCT03125902)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Paclitaxel
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 653 people
- Sponsor
- Hoffmann-La Roche
COVID-19
A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing
The negative global consequences of the COVID-19 pandemic has prompted efforts to develop efficient laboratory testing protocols that can be quickly scaled in a practical way.
- Trial name
- NCT04537572
- Testing
- comparison of sample collection methods
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salveo Diagnostics
Colitis, Ulcerative
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- PURSUIT 2 (NCT03596645)
- Testing
- Golimumab, Infliximab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Stage IB-IIB Cutaneous T-Cell Lymphoma
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma (CTCL) has a chronic, relapsing course with patients undergoing multiple, consecutive therapies. Treatment aims at the clearance of skin disease, minimization of recurrence, prevention of disease…
- Trial name
- MOGAT (NCT04128072)
- Testing
- Mogamulizumab, Total Skin Electron Beam Therapy (TSEB), Mogamulizumab (subsequent cycles post TSEB)
- Where
- 13 sites in Denmark, France and 5 more
- Volunteers
- 43 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Stage IV Melanoma
A Study of Volociximab in Metastatic Melanoma
This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab.
- Trial name
- NCT00369395
- Testing
- volociximab
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Abbott
Multiple Myeloma
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.
- Trial name
- NCT00425347
- Testing
- HuLuc63
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Facet Biotech
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
COVID-19, SARS-CoV-2
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
- Trial name
- NCT06039449
- Testing
- VYD222 (pemivibart), Normal saline
- Where
- 18 sites in United States
- Volunteers
- 790 people
- Sponsor
- Invivyd, Inc.
Metastatic Colorectal Cancer
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
This is a Phase II trial to study the safety and efficacy of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for…
- Trial name
- NCT01915472
- Testing
- IMMU 130
- Sponsor
- Gilead Sciences
Ovarian Cancer, Fallopian Tube Neoplasms
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but…
- Conditions
- Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00189345
- Testing
- anti-EpCAM x anti-CD3 (removab)
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- AGO Study Group
Breast Cancer, Gastric Cancer
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of zanidatamab in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04276493
- Testing
- Zanidatamab, Docetaxel, Tislelizumab
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 71 people
- Sponsor
- BeiGene
Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
- Conditions
- Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Trial name
- NCT07089121
- Testing
- Descartes-08
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cartesian Therapeutics
Lymphoma
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00072449
- Testing
- rituximab
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Healthy
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
This clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety of human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection and Adalimumab when used…
- Trial name
- NCT02912247
- Testing
- human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, adalimumab
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Influenza
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
This study will examine how various FDA-approved seasonal influenza vaccine types, used in a manner consistent with their approved use, impact the characteristics of influenza specific antibodies in humans, and how these…
- Trial name
- NCT04101838
- Testing
- Fluzone, Flucelvax, Fluzone High-Dose
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Autoimmune Diseases
Complement C5 mAb in the Treatment of Anti-GBM Disease
Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease.
- Trial name
- NCT06513338
- Testing
- Eculizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University First Hospital
Multiple Sclerosis, Relapsing-Remitting
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
This study will examine the safety of Zenapax (daclizumab) in patients with multiple sclerosis (MS). MS is thought to be caused by an over-reactive immune response.
- Trial name
- NCT00071838
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Prostate Cancer
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
This trial is a phase II, randomized, open label study designed to evaluate safety, tolerability and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity, and of VACXS15-PC01, a prostate cancer (PC)-specific…
- Trial name
- ImmProCure (NCT07860047)
- Testing
- PSMAxCD3, bispecific antibody CC-1, Multipeptide Vaccine VAC-XS15-PC01
- Where
- 4 sites in Germany
- Volunteers
- 84 people
- Sponsor
- University Hospital Tuebingen
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.